Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
Background: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing BRAF inhibitors during RT. There is a lack of dat...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Clinical and Translational Radiation Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630821000744 |
id |
doaj-c04c6894c51f4644bc1c102a9ceced0e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wei Wang Jessica Louise Smith Matteo Salvatore Carlino Bryan Burmeister Mark Blayne Pinkham Gerald Blaise Fogarty David Robert Harry Christie Vanessa Estall Mark Shackleton Arthur Clements Rory Wolfe Le Thi Phuong Thao Elizabeth Jane Paton Victoria Steel Narelle Catherine Williams |
spellingShingle |
Wei Wang Jessica Louise Smith Matteo Salvatore Carlino Bryan Burmeister Mark Blayne Pinkham Gerald Blaise Fogarty David Robert Harry Christie Vanessa Estall Mark Shackleton Arthur Clements Rory Wolfe Le Thi Phuong Thao Elizabeth Jane Paton Victoria Steel Narelle Catherine Williams Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma Clinical and Translational Radiation Oncology Melanoma Radiation therapy BRAF inhibitors MEK inhibitors Dabrafenib Trametinib |
author_facet |
Wei Wang Jessica Louise Smith Matteo Salvatore Carlino Bryan Burmeister Mark Blayne Pinkham Gerald Blaise Fogarty David Robert Harry Christie Vanessa Estall Mark Shackleton Arthur Clements Rory Wolfe Le Thi Phuong Thao Elizabeth Jane Paton Victoria Steel Narelle Catherine Williams |
author_sort |
Wei Wang |
title |
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma |
title_short |
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma |
title_full |
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma |
title_fullStr |
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma |
title_full_unstemmed |
Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma |
title_sort |
phase i/ii trial of concurrent extracranial palliative radiation therapy with dabrafenib and trametinib in metastatic braf v600e/k mutation-positive cutaneous melanoma |
publisher |
Elsevier |
series |
Clinical and Translational Radiation Oncology |
issn |
2405-6308 |
publishDate |
2021-09-01 |
description |
Background: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing BRAF inhibitors during RT. There is a lack of data regarding concurrent RT with combined BRAF and MEK inhibitors. This single-arm phase I/II trial was designed to assess the safety and tolerability of palliative RT with concurrent Dabrafenib and Trametinib in patients with BRAF-mutant metastatic melanoma. Materials and methods: Patients received Dabrafenib and Trametinib before and during palliative RT to soft tissue, nodal or bony metastases. The RT dose was escalated stepwise during the study period. Toxicity data including clinical photographs of the irradiated area was collected for up to 12 months following completion of RT. Results: Between June 2016 to October 2019, ten patients were enrolled before the study was stopped early due to low accrual rate. Six patients were treated at level 1 (20 Gy in 5 fractions, any location) and 4 patients at level 2a (30 Gy in 10 fractions with no abdominal viscera exposed). All alive patients completed one year of post-RT follow-up. Of the 82 adverse events (AEs) documented, the majority (90%) were grade 1 and 2. Eight grade 3 events (10%) occurred in five patients, only one was treatment-related (grade 3 fever due to Dabrafenib and Trametinib). No patients experienced grade 3 or 4 RT related toxicities, including skin toxicities. One serious AE was documented in relation to a grade 3 fever due to Dabrafenib and Trametinib requiring hospitalisation. Conclusions: The lack of grade 3 and 4 RT-related toxicities in our study suggests that Dabrafenib and Trametinib may be continued concurrently during fractionated non-visceral palliative RT to extracranial sites. |
topic |
Melanoma Radiation therapy BRAF inhibitors MEK inhibitors Dabrafenib Trametinib |
url |
http://www.sciencedirect.com/science/article/pii/S2405630821000744 |
work_keys_str_mv |
AT weiwang phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT jessicalouisesmith phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT matteosalvatorecarlino phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT bryanburmeister phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT markblaynepinkham phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT geraldblaisefogarty phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT davidrobertharrychristie phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT vanessaestall phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT markshackleton phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT arthurclements phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT rorywolfe phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT lethiphuongthao phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT elizabethjanepaton phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT victoriasteel phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma AT narellecatherinewilliams phaseiiitrialofconcurrentextracranialpalliativeradiationtherapywithdabrafenibandtrametinibinmetastaticbrafv600ekmutationpositivecutaneousmelanoma |
_version_ |
1721200233663168512 |
spelling |
doaj-c04c6894c51f4644bc1c102a9ceced0e2021-08-22T04:29:43ZengElsevierClinical and Translational Radiation Oncology2405-63082021-09-01309599Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous MelanomaWei Wang0Jessica Louise Smith1Matteo Salvatore Carlino2Bryan Burmeister3Mark Blayne Pinkham4Gerald Blaise Fogarty5David Robert Harry Christie6Vanessa Estall7Mark Shackleton8Arthur Clements9Rory Wolfe10Le Thi Phuong Thao11Elizabeth Jane Paton12Victoria Steel13Narelle Catherine Williams14Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW 2145, Australia; Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia; Corresponding author at: Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW 2145, Australia.Department of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW 2145, AustraliaDepartment of Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW 2145, Australia; Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, AustraliaGenesisCare, Fraser Coast, QLD 4655, AustraliaDepartment Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia; Queensland University of Technology, Brisbane City, QLD 4000, AustraliaMater Genesis Care Radiotherapy Centre, 25 Rocklands RD, Crows Nest, NSW 2065, AustraliaGenesiscare, Tugun, QLD 4224, Australia; Bond University, Robina, QLD 4226, AustraliaLiverpool Cancer Therapy Centre, Liverpool, NSW 2170, AustraliaDepartment of Oncology, Alfred Health, Melbourne, VIC 3004, Australia; Central Clinical School, Monash University, Melbourne, VIC 3004, AustraliaSAN Integrated Cancer Centre, Wahroonga, NSW 2076, AustraliaSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, AustraliaSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, AustraliaMelanoma and Skin Cancer Trials, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, AustraliaMelanoma and Skin Cancer Trials, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, AustraliaMelanoma and Skin Cancer Trials, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, AustraliaBackground: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing BRAF inhibitors during RT. There is a lack of data regarding concurrent RT with combined BRAF and MEK inhibitors. This single-arm phase I/II trial was designed to assess the safety and tolerability of palliative RT with concurrent Dabrafenib and Trametinib in patients with BRAF-mutant metastatic melanoma. Materials and methods: Patients received Dabrafenib and Trametinib before and during palliative RT to soft tissue, nodal or bony metastases. The RT dose was escalated stepwise during the study period. Toxicity data including clinical photographs of the irradiated area was collected for up to 12 months following completion of RT. Results: Between June 2016 to October 2019, ten patients were enrolled before the study was stopped early due to low accrual rate. Six patients were treated at level 1 (20 Gy in 5 fractions, any location) and 4 patients at level 2a (30 Gy in 10 fractions with no abdominal viscera exposed). All alive patients completed one year of post-RT follow-up. Of the 82 adverse events (AEs) documented, the majority (90%) were grade 1 and 2. Eight grade 3 events (10%) occurred in five patients, only one was treatment-related (grade 3 fever due to Dabrafenib and Trametinib). No patients experienced grade 3 or 4 RT related toxicities, including skin toxicities. One serious AE was documented in relation to a grade 3 fever due to Dabrafenib and Trametinib requiring hospitalisation. Conclusions: The lack of grade 3 and 4 RT-related toxicities in our study suggests that Dabrafenib and Trametinib may be continued concurrently during fractionated non-visceral palliative RT to extracranial sites.http://www.sciencedirect.com/science/article/pii/S2405630821000744MelanomaRadiation therapyBRAF inhibitorsMEK inhibitorsDabrafenibTrametinib |